期刊论文详细信息
Radiation Oncology
Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma
Norman F Kirkby3  Karen J Kirkby4  Jonathan C G Jeynes4  Lisiane B Meira1  Neil G Burnet2  Raj Jena2  Lara Barazzuol4 
[1] Department of Biochemistry and Physiology, Faculty of Health & Medical Sciences, University of Surrey, Guildford, Surrey, GU 7XH, UK;Department of Oncology, University of Cambridge, Oncology Centre, Addenbrooke’s Hospital, PO Box 193, Cambridge, CB2 0QQ, UK;Chemical and Process Engineering, Faculty of Engineering & Physical Sciences, University of Surrey, Guildford, Surrey, GU 7XH, UK;Ion Beam Centre, Faculty of Engineering & Physical Sciences, University of Surrey, Guildford, Surrey, GU2 7XH, UK
关键词: Temozolomide;    Radiation;    ABT-888;    PARP inhibition;    Glioblastoma;   
Others  :  1154369
DOI  :  10.1186/1748-717X-8-65
 received in 2012-11-09, accepted in 2013-03-12,  发布年份 2013
PDF
【 摘 要 】

Background

The cytotoxicity of radiotherapy and chemotherapy can be enhanced by modulating DNA repair. PARP is a family of enzymes required for an efficient base-excision repair of DNA single-strand breaks and inhibition of PARP can prevent the repair of these lesions. The current study investigates the trimodal combination of ABT-888, a potent inhibitor of PARP1-2, ionizing radiation and temozolomide(TMZ)-based chemotherapy in glioblastoma (GBM) cells.

Methods

Four human GBM cell lines were treated for 5 h with 5 μM ABT-888 before being exposed to X-rays concurrently with TMZ at doses of 5 or 10 μM for 2 h. ABT-888s PARP inhibition was measured using immunodetection of poly(ADP-ribose) (pADPr). Cell survival and the different cell death pathways were examined via clonogenic assay and morphological characterization of the cell and cell nucleus.

Results

Combining ABT-888 with radiation yielded enhanced cell killing in all four cell lines, as demonstrated by a sensitizer enhancement ratio at 50% survival (SER50) ranging between 1.12 and 1.37. Radio- and chemo-sensitization was further enhanced when ABT-888 was combined with both X-rays and TMZ in the O6-methylguanine-DNA-methyltransferase (MGMT)-methylated cell lines with a SER50 up to 1.44. This effect was also measured in one of the MGMT-unmethylated cell lines with a SER50 value of 1.30. Apoptosis induction by ABT-888, TMZ and X-rays was also considered and the effect of ABT-888 on the number of apoptotic cells was noticeable at later time points. In addition, this work showed that ABT-888 mediated sensitization is replication dependent, thus demonstrating that this effect might be more pronounced in tumour cells in which endogenous replication lesions are present in a larger proportion than in normal cells.

Conclusions

This study suggests that ABT-888 has the clinical potential to enhance the current standard treatment for GBM, in combination with conventional chemo-radiotherapy. Interestingly, our results suggest that the use of PARP inhibitors might be clinically significant in those patients whose tumour is MGMT-unmethylated and currently derive less benefit from TMZ.

【 授权许可】

   
2013 Barazzuol et al.; licensee BioMed Central Ltd.

【 预 览 】
附件列表
Files Size Format View
20150407104018207.pdf 1337KB PDF download
Figure 7. 144KB Image download
Figure 6. 94KB Image download
Figure 5. 59KB Image download
Figure 4. 46KB Image download
Figure 3. 62KB Image download
Figure 2. 59KB Image download
Figure 1. 38KB Image download
【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】
  • [1]Burnet NG, Jefferies SJ, Benson RJ, Hunt DP, Treasure FP: Years of life lost (YLL) from cancer is an important measure of population burden and should be considered when allocating research funds. Br J Cancer 2005, 92:241-245.
  • [2]Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO: European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
  • [3]Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005, 352:997-1003.
  • [4]Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA: DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008, 8:193-204.
  • [5]Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, Bontcheva-Diaz VD, Cox BF, DeWeese TL, Dillehay LE, Ferguson DC, Ghoreishi-Haack NS, Grimm DR, Guan R, Han EK, Holley-Shanks RR, Hristov B, Idler KB, Jarvis K, Johnson EF, Kleinberg LR, Klinghofer V, Lasko LM, Liu X, Marsh KC, McGonigal TP, Meulbroek JA, Olson AM, Palma JP, Rodriguez LE, Shi Y, Stavropoulos JA, Tsurutani AC, Zhu GD, Rosenberg SH, Giranda VL, Frost DJ: ABT-888, an orally active poly(ADPribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007, 13:2728-2737.
  • [6]Barazzuol L, Jena R, Burnet NG, Jeynes JC, Merchant MJ, Kirkby KJ, Kirkby NF: In vitro evaluation of combined temozolomide and radiotherapy using X rays and high-linear energy transfer radiation for glioblastoma. Radiat Res 2012, 177:651-662.
  • [7]Kirkby KJ, Grime GW, Webb RP, Kirkby NF, Folkard M, Prise K, Vojnovic B: A scanning focussed vertical ion nanobeam: A new UK facility for cell irradiation and analysis. Nucl Instrum Meth B 2007, 260:97-100.
  • [8]Clinical trial registry. http://clinicaltrials.gov/ webcite
  • [9]Clarke MJ, Mulligan EA, Grogan PT, Mladek AC, Carlson BL, Schroeder MA, Curtin NJ, Lou Z, Decker PA, Wu W, Plummer ER, Sarkaria JN: Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines. Mol Cancer Ther 2009, 8:407-414.
  • [10]Albert JM, Cao C, Kim KW, Willey CD, Geng L, Xiao D, Wang H, Sandler A, Johnson DH, Colevas AD, Low J, Rothenberg ML, Lu B: Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res 2007, 13:3033-3042.
  • [11]Horton TM, Jenkins G, Pati D, Zhang L, Dolan ME, Ribes-Zamora A, Bertuch AA, Blaney SM, Delaney SL, Hegde M, Berg SL: Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. Mol Cancer Ther 2009, 8:2232-2242.
  • [12]Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR, Ji J, Monks A, Low JA, Chen A, Murgo AJ, Collins J, Steinberg SM, Eliopoulos H, Giranda VL, Gordon G, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH: Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies. J Clin Oncol 2009, 27:2705-2111.
  • [13]Kummar S, Chen A, Ji J, Zhang Y, Reid JM, Ames M, Jia L, Weil M, Speranza G, Murgo AJ, Kinders R, Wang L, Parchment RE, Carter J, Stotler H, Rubinstein L, Hollingshead M, Melillo G, Pommier Y, Bonner W, Tomaszewski JE, Doroshow JH: Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas. Cancer Res 2011, 71:5626-5634.
  • [14]Valenzuela MT, Guerrero R, Núñez MI, Ruiz De Almodóvar JM, Sarker M, de Murcia G, Oliver FJ: PARP-1 modifies the effectiveness of p53-mediated DNA damage response. Oncogene 2002, 21:1108-1116.
  • [15]Wieler S, Gagné JP, Vaziri H, Poirier GG, Benchimol S: Poly(ADPribose) polymerase-1 is a positive regulator of the p53-mediated G1 arrest response following ionizing radiation. J Biol Chem 2003, 278:18914-18921.
  • [16]The Cancer Genome Atlas (TCGA) Research Network: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068.
  • [17]Chalmers AJ: Overcoming resistance of glioblastoma to conventional cytotoxic therapies by the addition of PARP inhibitors. Anticancer Agents Med Chem 2010, 10:520-533.
  • [18]Noël G, Godon C, Fernet M, Giocanti N, Mégnin-Chanet F, Favaudon V: Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the S phase of the cell cycle and involves arrest of DNA synthesis. Mol Cancer Ther 2006, 5:564-574.
  • [19]Dungey FA, Lӧ ser DA, Chalmers AJ: Replication-dependent radiosensitization of human glioma cells by inhibition of poly (ADP-Ribose) polymerase: mechanisms and therapeutic potential. Int J Radiat Oncol Biol Phys 2008, 72:1188-1197.
  • [20]Efimova EV, Mauceri HJ, Golden DW, Labay E, Bindokas VP, Darga TE, Chakraborty C, Barreto-Andrade JC, Crawley C, Sutton HG, Kron SJ, Weichselbaum RR: Poly(ADP-ribose) polymerase inhibitor induces accelerated senescence inirradiated breast cancer cells and tumors. Cancer Res 2010, 70:6277-6282.
  • [21]Liu SK, Coackley C, Krause M, Jalali F, Chan N, Bristow RG: A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia. Radiother Oncol 2008, 88:258-268.
  • [22]Wilson GD, Bentzen SM, Harari PM: Biologic basis for combining drugs with radiation. Semin Radiat Oncol 2006, 16:2-9.
  • [23]Hei TK, Piao CQ, Geard CR, Hall EJ: Taxol and ionizing radiation: interaction and mechanisms. Int J Radiat Oncol Biol Phys 1994, 29:267-271.
  • [24]Palma JP, Wang YC, Rodriguez LE, Montgomery D, Ellis PA, Bukofzer G, Niquette A, Liu X, Shi Y, Lasko L, Zhu GD, Penning TD, Giranda VL, Rosenberg SH, Frost DJ, Donawho CK: ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin Cancer Res 2009, 15:7277-7290.
  • [25]van Rijn J, Heimans JJ, van den Berg J, van der Valk P, Slotman BJ: Survival of human glioma cells treated with various combination of temozolomide and X-rays. Int J Radiat Oncol Biol Phys 2000, 47:779-784.
  • [26]Chakravarti A, Erkkinen MG, Nestler U, Stupp R, Mehta M, Aldape K, Gilbert MR, Black PM, Loeffler JS: Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin Cancer Res 2006, 12:4738-4746.
  • [27]van Nifterik KA, van den Berg J, Stalpers LJ, Lafleur MV, Leenstra S, Slotman BJ, Hulsebos TJ, Sminia P: Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines. Int J Radiat Oncol Biol Phys 2007, 69:1246-1253.
  • [28]Kil WJ, Cerna D, Burgan WE, Beam K, Carter D, Steeg PS, Tofilon PJ, Camphausen K: In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide. Clin Cancer Res 2008, 14:931-938.
  • [29]Wedge SR, Porteous JK, Glaser MG, Marcus K, Newlands ES: In vitro evaluation of temozolomide combined with X-irradiation. Anti-cancer drugs 1997, 8:92-97.
  • [30]Hermisson M, Klumpp A, Wick W, Wischhusen J, Nagel G, Roos W, Kaina B, Weller M: O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem 2006, 96:766-776.
  • [31]Combs SE, Schulz-Ertner D, Roth W, Herold-Mende C, Debus J, Weber KJ: In vitro responsiveness of glioma cell lines to multimodality treatment with radiotherapy, temozolomide, and epidermal growth factor receptor inhibition with cetuximab. Int J Radiat Oncol Biol Phys 2007, 68:873-882.
  • [32]Chalmers AJ, Ruff EM, Martindale C, Lovegrove N, Short SC: Cytotoxic effects of temozolomide and radiation are additive- and schedule-dependent. Int J Radiat Oncol Biol Phys 2009, 75:1511-9.
  • [33]Liu X, Shi Y, Guan R, Donawho C, Luo Y, Palma J, Zhu GD, Johnson EF, Rodriguez LE, Ghoreishi-Haack N, Jarvis K, Hradil VP, Colon-Lopez M, Cox BF, Klinghofer V, Penning T, Rosenberg SH, Frost D, Giranda VL, Luo Y: Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to doublestranded DNA breaks. Mol Cancer Res 2008, 6:1621-1629.
  • [34]Nowsheen S, Bonner JA, Lobuglio AF, Trummell H, Whitley AC, Dobelbower MC, Yang ES: Cetuximab augments cytotoxicity with poly (ADPribose) polymerase inhibition in head and neck cancer. PLoS One 2011, 6:1-11.
  • [35]Huehls AM, Wagner JM, Huntoon CJ, Geng L, Erlichman C, Patel AG, Kaufmann SH, Karnitz LM: Poly(ADP-ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells. Cancer Res 2011, 71:4944-4954.
  文献评价指标  
  下载次数:10次 浏览次数:7次